HemaQuest Raises $4M More, Boosting VC Round to $16M for Sickle Cell, Blood Disorders
Xconomy -- Another few months have gone by, and another few million bucks have arrived in the corporate treasury for HemaQuest Pharmaceuticals. The Seattle-based developer is announcing today it has raised $4 million for its experimental treatments for sickle cell anemia and other blood disorders.